Company
Bioxyne (BXN:ASX) is an international healthcare, life sciences and novel medicines development company with operations in Australia (head office), United Kingdom, Japan, , , Czechia, Germany, and the United States serving customers world-wide.
Scroll Down
Bioxyne
Our History
Bioxyne (BXN:ASX) is an international healthcare, life sciences and novel medicines development company with operations in Australia (head office), United Kingdom, Japan, Czechia, Germany, and the United States serving customers world-wide.
Bioxyne has a rich history in clinical research and development of efficacious health and wellness products. Since the acquisition of BLS in 2023 the group has maintained this core value and improved its delivery by extending into new dose formats, active ingredients, and markets.
2025 has been a year of significant growth for Bioxyne and marks the Company’s expansion of its established health and wellness operations into pharmaceutical and health product manufacturing in Australia following GMP licensing by the TGA in February 2024.
Our ability to rapidly scale manufacturing operations in Australia has laid the groundwork to further extend our business model in other key markets. In 2026 we continue to scale up our Australian business, and expand our operations in international markets, such as Germany, the United Kingdom and Europe.
Our Vision and Mission
Our mission is to be a global leader in the manufacture and supply of innovative medicines and healthcare solutions, pioneering next-generation treatments for mental and physical diseases. We are committed to advancing medical science, contributing to the global pharmacopeia, and ensuring the highest quality standards for our products and patients worldwide.
Throughout history, humans have relied on plants not only for nutrition but also for healing. As science advanced, plant-based medicine evolved into a major industry, giving rise to compounds such as aspirin and other life-changing drugs. Many modern pharmaceuticals still originate from plants and fungi, yet vast potential remains undiscovered.
In recent years, renewed legislation has opened the door to studying and using previously restricted plant- and fungus-derived compounds for therapeutic purposes. We are proud to stand at the forefront of this new era in healthcare innovation.
What We Do
Activities
- Breathe Life Sciences (BLS) manufactures and distributes health, wellness, and medicinal products. Its activities include contract manufacturing of finished dose forms and APIs, plus distribution of CBD, probiotics (PCC), mushroom extracts (e.g. Lion’s Mane), medicinal cannabis, MDMA, and psilocybin across Australia, the UK, and Europe.
- Dr Watson® offers branded health and prescription products, made by BLS and partners, sold in Australia, the UK, Germany, and Japan. The range spans capsules, tablets, oral solutions, and herbal preparations with actives such as Lactobacillus Fermentum PCC®, mushrooms, SL-NAD+, and cannabis-based ingredients.
- Research & Development focuses on new formulations and manufacturing processes, including patented probiotic capsules, MDMA and psilocybin products for clinical use, and efficiency improvements across operations.
Our Solutions
The Team
Bioxyne Leadership Team
The BXN/ BLS team is composed of highly dedicated and passionate individuals from around the world, working together for a common purpose: To change the way we think about and treat disease, and to combat mental and physical disease with novel forms of medicines.
We are at the forefront of seismic change in the pharmaceutical industry, and we aim to be a leading global player in preventative medicine, alternative medicines, patient access, and pre-pharmacuetical health care.